Advertisement
Organisation › Details
Alvotech hf
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech is headquartered in Iceland and employs over 900 people world-wide, with offices in the U.S., Germany, Switzerland and India. Alvotech's shares are listed on the Nasdaq U.S. Stock Exchange and Nasdaq Iceland First North market under the symbol ALVO. *
Start | 2013-01-01 established | |
Group | Alvogen (Group) | |
Industry | DRUGS, BIOGEN, GENERICS (biosimilars / biogenerics) | |
Region | Reykjavík | |
Country | Iceland | |
Street | 15–19 Saemundargata | |
City | 101 Reykjavík | |
Address record changed: 2020-04-10 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: MiGenTra GmbH. (11/29/22). "Press Release: Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa". | ||
Record changed: 2024-02-12 |
Advertisement
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top